Published: 2022 June 22

CAR T-Cell Therapy – Pipeline Insights – 2018

SKU : 937
180 pages
Table of Contents
Report Summary

CAR T-cell Therapies

01: Executive Summary


02: Scope of the Report


03: Introduction

3.1 CAR T-cell Therapies – Overview

3.2 CAR T-cell Therapies –Role in the treatment of various types of tumors


04: CAR T-cell Therapies – Pipeline Landscape

4.1 Overview of Pipeline CAR T-cell Therapies

4.2 CAR T-cell Therapies Filed and Phase III Products

4.3 Comparative Analysis

4.4 CAR T-cell Therapies Phase II Products

4.5 Comparative Analysis

4.6 CAR T-cell Therapies Phase I and IND Filed Products

4.7 Comparative Analysis

4.8 CAR T-cell Therapies Discovery and Pre-Clinical Stage Products

4.9 Comparative Analysis

4.10 CAR T-cell Therapies – Discontinued Products

4.11 CAR T-cell Therapies – Dormant Products


05: CAR T-cell Therapies by molecule type

5.1 Small molecule

5.2 Gene Therapies

5.3 Others


06: Comparative Analysis of Marketed and Pipeline CAR T-cell Therapies


07: Key Pipeline Product Profiles


08: Competitive Landscape

8.1 Prominent Vendors:

8.1a Celgene

8.2 Other Prominent Vendors:

8.2a Aeon Therapeutics

8.2b Autolus

8.2c Bellicum

8.2d Beijing Immunochina

8.2e Celyad

8.2f Eureka

8.2g Juno

8.2h Kite

8.2i Intrexon

8.2j Marino Biotechnology

8.2k Pinze Lifetechnology

8.2l Shanghai Unicar-Therapy

8.2m Sinobioway cell Therapy

8.2n Sirtex Medical

8.2o Ziopharm


09: Key News

9.1 Major Mergers and Acquisitions

9.2 Product News (including clinical trial progression updates)



Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy